WallStreetZenWallStreetZen

NASDAQ: ALVR
Allovir Inc Stock

$0.76+0.01 (+1.33%)
Updated Mar 27, 2024
ALVR Price
$0.76
Fair Value Price
$0.60
Market Cap
$87.42M
52 Week Low
$0.62
52 Week High
$6.12
P/E
-0.42x
P/B
0.6x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$190.42M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.31
Operating Cash Flow
-$124M
Beta
1.68
Next Earnings
May 2, 2024
Ex-Dividend
N/A
Next Dividend
N/A

ALVR Overview

Allovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus. Its preclinical and clinical development product candidates include ALVR106 for the respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109 to treat SARS-CoV-2 and COVID-19; ALVR107 for treating hepatitis B; and ALVR108. The company was formerly known as ViraCyte, Inc. and changed its name to Allovir, Inc. in May 2019. Allovir, Inc. was founded in 2013 and is based in Waltham, Massachusetts.

Zen Score

Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how ALVR scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

ALVR ($0.76) is overvalued by 26.31% relative to our estimate of its Fair Value price of $0.60 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
ALVR ($0.76) is not significantly undervalued (26.31%) relative to our estimate of its Fair Value price of $0.60 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
ALVR is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more ALVR due diligence checks available for Premium users.

Be the first to know about important ALVR news, forecast changes, insider trades & much more!

ALVR News

Valuation

ALVR fair value

Fair Value of ALVR stock based on Discounted Cash Flow (DCF)
Price
$0.76
Fair Value
$0.60
Overvalued by
26.15%
ALVR ($0.76) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
ALVR ($0.76) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
ALVR is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

ALVR price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-0.42x
Industry
14.3x
Market
44.45x

ALVR price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
0.6x
Industry
6.2x
ALVR is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

ALVR's financial health

Profit margin

Revenue
$0.0
Net Income
-$59.7M
Profit Margin
0%
ALVR's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials

Assets to liabilities

Assets
$190.8M
Liabilities
$45.0M
Debt to equity
0.31
ALVR's short-term assets ($187.64M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
ALVR's short-term assets ($187.64M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
ALVR's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
ALVR's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$30.7M
Investing
$25.2M
Financing
$11.0k
ALVR's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

ALVR vs Biotech Stocks

TickerMarket Cap1d %P/EP/B
ALVR$87.42M+1.47%-0.42x0.60x
VAXX$87.33M+6.00%-1.53x6.51x
CRVS$87.78M+1.70%-3.20x2.27x
BTAI$88.06M+0.70%-0.47x-1.56x
RVPH$88.34M+1.83%-2.34x-10.37x

Allovir Stock FAQ

What is Allovir's quote symbol?

(NASDAQ: ALVR) Allovir trades on the NASDAQ under the ticker symbol ALVR. Allovir stock quotes can also be displayed as NASDAQ: ALVR.

If you're new to stock investing, here's how to buy Allovir stock.

What is the 52 week high and low for Allovir (NASDAQ: ALVR)?

(NASDAQ: ALVR) Allovir's 52-week high was $6.12, and its 52-week low was $0.62. It is currently -87.57% from its 52-week high and 22.15% from its 52-week low.

How much is Allovir stock worth today?

(NASDAQ: ALVR) Allovir currently has 114,869,175 outstanding shares. With Allovir stock trading at $0.76 per share, the total value of Allovir stock (market capitalization) is $87.42M.

Allovir stock was originally listed at a price of $25.85 in Aug 3, 2020. If you had invested in Allovir stock at $25.85, your return over the last 3 years would have been -97.06%, for an annualized return of -69.12% (not including any dividends or dividend reinvestments).

How much is Allovir's stock price per share?

(NASDAQ: ALVR) Allovir stock price per share is $0.76 today (as of Mar 27, 2024).

What is Allovir's Market Cap?

(NASDAQ: ALVR) Allovir's market cap is $87.42M, as of Mar 29, 2024.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Allovir's market cap is calculated by multiplying ALVR's current stock price of $0.76 by ALVR's total outstanding shares of 114,869,175.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.